Survival and late effects in the risk-stratified hepatoblastoma patients treated by JPLT-2 protocol.

被引：0
|
作者：
Hiyama, Eiso
Kurihara, Sho
Ueda, Yuka
Hishiki, Tomoro
Ida, Kohmei
Iehara, Tomoko
Oue, Takaharu
Yano, Michihiro
Watanabe, Kenichiro
Hoshino, Ken
Ko, Katsuyoshi
Tanaka, Yukichi
机构：
[1] Hiroshima Univ, Hiroshima, Japan
[2] Hiroshima Univ Hosp, Hiroshima, Japan
[3] Japanese Study Grp Pediat Liver Tumor, Hiroshima, Japan
[4] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Pediat, Kyoto, Japan
[5] Japanese Study Grp Pediat Liver Tumor, Osaka, Japan
[6] Japanese Study Grp Pediat Liver Tumor, Tokyo, Japan
[7] Japanese Study Grp Pediat Liver Tumor, Saitama, Japan
[8] Japanese Study Grp Pediat Liver Tumor, Yokohama, Kanagawa, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10021
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Dose-volume analyses of grade ≥ 2 late rectal toxicity among patients treated on protocol RTOG 94-06
    Cheung, M. R.
    Tucker, S. L.
    Dong, L.
    Bosch, W. R.
    Michalski, J.
    Winter, K.
    Mohan, R.
    Kuban, D.
    Lee, A. K.
    Cox, J. D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (03): : S9 - S9
  • [42] LDH is an important risk factor to predict survival in patients with MDS treated with 5-aza-2'-deoxycytidine (Decitabine).
    Wijermans, PW
    Luebbert, M
    Verhoef, G
    BLOOD, 2003, 102 (11) : 424A - 424A
  • [43] Transplant Outcomes in High-Risk (Class 3) Patients with Thalassemia Treated with a Modified Protocol Are Equivalent to Low/Intermediate-Risk (Class 1/Class 2) Patients
    Gaziev, Javid
    De Angelis, Gioia
    Isgro, Antonella
    Sodani, Pietro
    Marziali, Marco
    Paciaroni, Katia
    Andreani, Marco
    Testi, Manuela
    Gallucci, Cristiano
    Alfieri, Cecilia
    Ribersani, Michela
    Troiano, Maria
    Morrone, Aldo
    Lucarelli, Guido
    BLOOD, 2015, 126 (23)
  • [44] EARLY AND LATE SIDE EFFECTS IN PATIENTS WITH OROPHARYNGEAL AND HYPOPHARYNGEAL CANCER TREATED WITH IMRT and CONVENTIONAL 2D RADIOTHERAPY
    Tayel, A.
    Shenouda, G.
    Sultanem, Kh.
    Cury, F.
    RADIOTHERAPY AND ONCOLOGY, 2009, 92 : S50 - S50
  • [45] Effects of protocol-driven care versus usual outpatient clinic care on survival rates in patients with type 2 diabetes
    So, WY
    Tong, PCY
    Ko, GTC
    Leung, WYS
    Chow, CC
    Yeung, VTF
    Chan, WB
    Critchley, JAJH
    Cockram, CS
    Chan, JCN
    AMERICAN JOURNAL OF MANAGED CARE, 2003, 9 (09): : 606 - 615
  • [46] NQO1*2 POLYMORPHISM DOES NOT PREDICT OVERALL SURVIVAL IN HIGHER RISK MDS PATIENTS TREATED WITH 5-AZACYTIDINE
    Moudra, A.
    Vancurova, M.
    Machalova, V.
    Hodny, Z.
    Bartek, J.
    Jonasova, A.
    LEUKEMIA RESEARCH, 2015, 39 : S136 - S137
  • [47] Tumor ploidy as a risk factor for disease recurrence and short survival in surgically treated Dukes' B2 colon cancer patients
    Nori, D
    Merimsky, O
    Saw, D
    Cortes, E
    Chen, E
    Chassin, J
    TUMOR BIOLOGY, 1996, 17 (02) : 75 - 80
  • [48] Bariatric surgery in patients with late-stage type 2 diabetes: expected beneficial effects on risk ratio and outcomes
    Renard, E.
    DIABETES & METABOLISM, 2009, 35 (06) : 564 - 568
  • [49] Survival benefit of high dose therapy over sequential chemotherapy in poor risk aggressive non-Hodgkin's lymphoma. Final analysis of the prospective LNH87-2 protocol. A gela study.
    Haioun, C
    Lepage, E
    Gisselbrecht, C
    Salles, G
    Coiffier, B
    Brice, P
    Bosly, A
    Morel, P
    Nouvel, C
    Tilly, H
    Lederlin, P
    Sebban, C
    Briere, J
    Gaulard, P
    Reyes, F
    BLOOD, 1999, 94 (10) : 610A - 610A
  • [50] THE EFFECTS OF GnRH ANTAGONIST SINGLE DOSE (0.25MG) ON THE PREVENTION OF OVARIAN HYPERSTIMULATION SYNDROME (OHSS) IN PATIENTS WITH HIGH E2 LEVELS BY COH IN A STANDARD GnRH AGONIST LONG PROTOCOL.
    Kim, Y. Y.
    Jung, Y. H.
    Kim, M. H.
    Cho, J. D.
    FERTILITY AND STERILITY, 2010, 94 (04) : S166 - S166
12345